- Two separate market research reports predict 7.0 percent and 2.9 percent CAGR, respectively, in PreveCeutical’s areas of operation
- PreveCeutical developing Sol-Gel, an innovative medicine delivery platform
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is uniquely positioned to capitalize of the growth of two different markets in which it currently operates: dietary supplements and drug delivery systems. Two separate market research reports indicated recently that these sectors are expected to grow a projected 7.0 percent and 2.9 percent, respectively, over the next five years.
In a report published in May, Technavio estimated that the global dietary supplements market will post a compound annual growth rate (CAGR) of 7.0 percent between 2018 and 2022 (http://nnw.fm/PsmE2). Meanwhile, also in May, Mordor Intelligence predicted that the novel drug delivery systems market will have a CAGR of 2.9 percent over the same period (http://nnw.fm/kts2N).
This is positive news for PreveCeutical, an innovator in preventative therapies and the developer of a unique medicine delivery platform based on cannabidiol (CBD), Sol-Gel, which will allow medicines to be applied through the nose and delivered directly to the brain.
Research has shown CBD to be non-psychoactive and to have anti-inflammatory, anti-anxiety and anti-emetic properties (http://nnw.fm/z2D8Y). Following nasal administration, the formulations gel rapidly with mucosal tissue to facilitate direct nose-to-brain delivery of cannabinoids. The gel substantially improves bioavailability and provides controlled cannabinoid release, staying in the nasal passages for up to seven days.
PreveCeutical’s groundbreaking Sol-Gel delivery system displays significant benefits over other contemporary delivery systems. It bypasses first pass metabolism in the stomach, intestines and liver, exhibiting a dramatic improvement in bioavailability, even compared to nasal sprays and alternative delivery mechanisms. Unlike other delivery systems, PreveCeutical’s Sol-Gel delivery technology enables ease of application and provides long-lasting effects.
A number of delivery challenges often impact the effectiveness of medicines. Issues like high pill burdens and needle phobia can affect patient’s adherence to treatment. Some medical formulations contain harsh solvents which may lead to unwanted side effects, while other delivery modes pose challenges for patients with unique needs, such as children. Through the ease and simplicity of application, Sol-Gels address several of these challenges.
PreveCeutical is also developing solutions based on the peptides derived from Caribbean Blue Scorpion venom for pain management, cancer, cardiovascular conditions, metabolic disorders and infectious diseases.
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
